![]() MannKind Corporation MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients. | Kadimastem Kadimastem is a biopharmaceutical company that develops industrial regenerative medicine therapies based on differentiated cells derived from human embryonic stem cells (hESCs). | Antag Therapeutics Antag Therapeutics is a preclinical-stage biotechnology company focused on developing therapies for dietary-related metabolic diseases. | |||
Founding Date | Founding Date 2011 | Founding Date 1991 | Founding Date 2014 | Founding Date 2009 | Founding Date 2017 |
Type | Type Public | Type Public | Type Private | Type Public | Type Subsidiary |
Tags | |||||
Locations | Locations Lund, SE HQ | Locations Westlake Village, US HQ Danbury, US | Locations Malmö, SE HQ | Locations Ness Ziona, IL HQ | Locations København, DK HQ |
Employees | Employees N/A | Employees 39513% increase | Employees 9 | Employees 11 | Employees 20 |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $349m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $26.8m (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit kr357k (FY, 2021) | Gross profit $322.2m (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit (kr13.1m) (FY, 2021) |
Net income | Net income (kr24.2m) (FY, 2021) | Net income $5.9m (FY, 2025) | Net income N/A | Net income (₪26.6m) (FY, 2024) | Net income (kr14.9m) (FY, 2021) |

MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.
View companyKadimastem is a biopharmaceutical company that develops industrial regenerative medicine therapies based on differentiated cells derived from human embryonic stem cells (hESCs).
View companyAntag Therapeutics is a preclinical-stage biotechnology company focused on developing therapies for dietary-related metabolic diseases.
View company